TIDMINS

RNS Number : 6269L

Instem plc

14 September 2021

Instem plc

("Instem")

Notice of Results and Investor Presentation

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, will announce results for the half year ended 30 June 2021 on Monday 27 September 2021.

Investor Presentation: 4.00pm, Monday 27 September

Management will be providing a presentation and hosting an Investor Q&A session on the results and future prospects, as well as the recent acquisition of PDS Pathology Data Systems Ltd on the day of results, at 4.00pm. Investors can sign up for free and add to attend the presentation via the following link: https://www.investormeetcompany.com/instem-plc/register-investor

Questions can be submitted pre-event and at any time during the live presentation via the Investor Meet Company Platform.

Analyst Presentation: 11:30am, Monday 27 September

Management will be hosting a presentation via web conference on the day of the results at 11.30am. Analysts wishing to join should register their interest by emailing instem@walbrookpr.com or by telephoning 020 7933 8780.

For further information, please contact:

 
 Instem plc                           Via Walbrook 
 Phil Reason, CEO 
 Nigel Goldsmith, CFO 
 
 Singer Capital Markets (Nominated 
  Adviser & Broker)                   +44 (0) 20 7496 3000 
 Peter Steel 
  Alex Bond 
  Rachel Hayes 
 
 Walbrook Financial PR                +44 (0) 20 7933 8780 
 Tom Cooper                           instem@walbrookpr.com 
 Nick Rome 
  Nicholas Johnson

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study ManagementRegulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

To learn more about Instem solutions and its mission, please visit www.instem.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORSFDFWDEFSESU

(END) Dow Jones Newswires

September 14, 2021 02:00 ET (06:00 GMT)

Instem (LSE:INS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Instem.
Instem (LSE:INS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Instem.